CN112741334B - Prebiotic compositions, and uses thereof - Google Patents

Prebiotic compositions, and uses thereof Download PDF

Info

Publication number
CN112741334B
CN112741334B CN201911036025.6A CN201911036025A CN112741334B CN 112741334 B CN112741334 B CN 112741334B CN 201911036025 A CN201911036025 A CN 201911036025A CN 112741334 B CN112741334 B CN 112741334B
Authority
CN
China
Prior art keywords
weight
bifidobacterium animalis
composition
parts
oligosaccharide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201911036025.6A
Other languages
Chinese (zh)
Other versions
CN112741334A (en
Inventor
石羽杰
刘彪
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Inner Mongolia Yili Industrial Group Co Ltd
Original Assignee
Inner Mongolia Yili Industrial Group Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inner Mongolia Yili Industrial Group Co Ltd filed Critical Inner Mongolia Yili Industrial Group Co Ltd
Priority to CN201911036025.6A priority Critical patent/CN112741334B/en
Publication of CN112741334A publication Critical patent/CN112741334A/en
Application granted granted Critical
Publication of CN112741334B publication Critical patent/CN112741334B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/20Reducing nutritive value; Dietetic products with reduced nutritive value
    • A23L33/21Addition of substantially indigestible substances, e.g. dietary fibres
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23CDAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
    • A23C9/00Milk preparations; Milk powder or milk powder preparations
    • A23C9/12Fermented milk preparations; Treatment using microorganisms or enzymes
    • A23C9/123Fermented milk preparations; Treatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceae; Yoghurt
    • A23C9/1234Fermented milk preparations; Treatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceae; Yoghurt characterised by using a Lactobacillus sp. other than Lactobacillus Bulgaricus, including Bificlobacterium sp.
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23CDAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
    • A23C9/00Milk preparations; Milk powder or milk powder preparations
    • A23C9/16Agglomerating or granulating milk powder; Making instant milk powder; Products obtained thereby
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135Bacteria or derivatives thereof, e.g. probiotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7016Disaccharides, e.g. lactose, lactulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/733Fructosans, e.g. inulin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66Microorganisms or materials therefrom
    • A61K35/74Bacteria
    • A61K35/741Probiotics
    • A61K35/744Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/745Bifidobacteria
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12Antidiarrhoeals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23VINDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00Food compositions, function of food ingredients or processes for food or foodstuffs
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23VINDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2400/00Lactic or propionic acid bacteria
    • A23V2400/51Bifidobacterium
    • A23V2400/515Animalis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Nutrition Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention belongs to the technical field of food or medicine, and particularly relates to a prebiotic composition, which comprises the following components: 0.5-18 parts of oligosaccharide and 1 part of isomerized lactose; wherein the oligosaccharide is at least one selected from galacto-oligosaccharide, fructo-oligosaccharide and raffinose. The invention also relates to a (synbiotic) composition containing the prebiotic composition and bifidobacterium animalis, and applications thereof. The prebiotic composition can obviously promote the proliferation of BB12, and can be used for preventing or treating diarrhea, intestinal flora disorder caused by antibiotics, and intestinal flora disorder or respiratory infection diseases caused by iron supplement.

Description

Prebiotic compositions, and uses thereof
Technical Field
The invention belongs to the technical field of food or medicine, and particularly relates to a prebiotic composition, a composition containing the prebiotic composition and animal bifidobacteria, and food or medicine application of the prebiotic composition and the composition.
Background
World Food and Agriculture Organization (FAO) and World Health Organization (WHO) on probioticsThe definition of bacteria is: live bacteria which exert an effective effect on the health of the consumer can be ingested in an appropriate amount. Among many probiotics, bifidobacteria have been attracting attention. A number of studies have shown that bifidobacteria are closely related to human life health and disease, as shown in FIG. 1 [1] : in the early life stage, the bifidobacteria in intestinal bacteria of a human body account for about 60-70 percent, and the deficiency of the bifidobacteria can cause the newborn to suffer from diseases such as necrotizing enterocolitis, allergy, IBS (IBS-induced bowel disease) and the like; in early adulthood, the bifidobacteria in intestinal bacteria of human body account for about 30-40%, and the bifidobacteria level gradually decreases along with the increase of the age in adulthood, and the lack of the bifidobacteria can cause diseases such as obesity, diabetes and the like; in the elderly, the level of bifidobacteria in the human intestinal tract is further reduced, accounting for about 0-5% of the intestinal bacteria, and the lack of bifidobacteria may lead to cancer and geriatric diseases. The number of bifidobacteria in the intestinal tract of healthy individuals and long-lived people is relatively high. It has been shown that the proportion of bifidobacteria in the faeces of formula-fed infants is significantly lower than that of breast-fed infants, which has a significant effect on the early intestinal micro-ecology of infants, and that by adding bifidobacteria probiotics to infant formula it is possible to adjust the intestinal micro-ecology of formula-fed infants closer to that of breast-fed infants, especially the proportion of bifidobacteria. Bifidobacteria are also associated with a number of potential health-promoting metabolites, including short-chain fatty acids, conjugated linoleic acid and bacteriocins.
Bifidobacterium animalis, bifidobacterium lactis BB-12, which is the most well-documented Bifidobacterium worldwide, is described in over 300 scientific publications, of which over 130 publications relate to human clinical studies, the complete genomic sequence of BB-12 has been drawn and published, numerous in vitro tests have established the strain characteristics and mechanisms of BB-12, BB-12 exhibits excellent acid bile tolerance, contains bile salt hydrolase and has strong adhesion, and these are valuable probiotic properties. The health-care effects of BB-12 were validated in many clinical studies of gastrointestinal health and immune function, which demonstrated: BB-12 survives through the gastrointestinal tract [2-4] And can maintain the health of the gastrointestinal flora, and BB-12 can maintain the balance and health of the intestinal microecologyTreating diarrhea, including diarrhea caused by antibiotic therapy [5-7] (ii) a In the aspect of immune function, clinical researches show that BB-12 can improve the resistance of an organism to common respiratory tract infection and reduce the incidence rate of acute respiratory tract infection, and the experiments prove that BB-12 inhibits pathogenic bacteria, enhances barrier function and interacts with immunity [2,8-12] . BB-12 has high stability in food, and the stability of freeze-dried powder prepared from the BB-12 is also good. For healthy people, including term newborns, BB-12 is considered safe as a dietary ingredient and dietary supplement in food products.
Prebiotics are a class of carbohydrates that are not digestible by the human body and interact with the intestinal flora in the host's gut to produce substances or effects that are beneficial to the host. The prebiotics currently under investigation include galacto-oligosaccharides, fructo-oligosaccharides, inulin, isomerized lactose, polydextrose, xylo-oligosaccharides, and the like.
The galacto-oligosaccharide (GOS) has a structure in which 1 to 7 galactosyl groups are bonded to galactosyl groups of lactose mainly through beta-1, 4-glycosidic bonds, and is obtained by transglycosidation conversion of beta-D-galactosidase with disaccharide lactose as a reaction substrate, and is a hetero-oligosaccharide formed by combining galactose and glucose. The glucosyl and galactosyl in the GOS structure are connected by beta-1, 4-glycosidic bond, and the adjacent galactosyl is connected by beta-1, 3, beta-1, 4 and beta-1, 6-glycosidic bond, wherein the beta-1, 4-glycosidic bond is taken as the main bond, and the main bonds comprise galacto-oligosaccharides, tetrasaccharides, a small amount of pentasaccharides, hexasaccharides and the like. In addition, the beta-D-galactosidase of some microorganisms can catalyze the synthesis of galactooligosaccharides structurally different from lactose, linked by beta-1, 3 and beta-1, 6-glycosidic bonds, from glucose and galactose produced by hydrolysis of the substrate lactose. Animal milk contains a small amount of GOS, and human breast milk contains a little more. The structure of galacto-oligosaccharides (GOS) is shown by the following formula:
Figure BDA0002251528160000031
molecular structure of Galactooligosaccharides (GOS).
The fructo-oligosaccharide is functional oligosaccharide with beta (2-1) glycosidic bond connection and polymerization degree of 2-9, belongs to food ingredients, and is widely present in fruits, vegetables and other substances. According to different production raw materials and processes, the fructo-oligosaccharide can be divided into two types on the whole, one type is inulin fructo-oligosaccharide, the production raw material is inulin extracted from chicory or jerusalem artichoke, the inulin is generated by enzymolysis or acidolysis, the main structural form of the fructo-oligosaccharide is Fn type (F is fructose, and n is the number of the fructose), and the fructo-oligosaccharide also contains a certain amount of GFn type; the other is sucrose fructo-oligosaccharide, the production raw material is sucrose, and the sucrose fructo-oligosaccharide, tetrasaccharide, pentasaccharide, hexasaccharide and the mixture thereof are generated by the action of enzyme, and the structural form of the sucrose fructo-oligosaccharide is GFn type. The two fructooligosaccharides are slightly different in structure, but have substantially the same physiological function. The structures of GFn type and Fn type are shown as follows:
Figure BDA0002251528160000032
chemical structures of GFn-type (left) and Fn-type (right).
Isomerized lactose is the earliest prebiotic found, then called the "bifidus factor", and has a good promoting effect on the growth of bifidobacteria. The isomerized lactose is a disaccharide, and has various physicochemical advantages of low sweetness, good acid resistance and good heat stability.
Synbiotics generally refers to a combination of probiotics and prebiotics, wherein the prebiotics enhance the growth and reproduction ability of the probiotics, the survival ability in the intestinal system, and thus provide health benefits to the host. The top experts of the organization of ISAPP (International scientific Association for Probiotics and Prebiotics) in 2019 at 5 months are trying to demonstrate a definition of synbiotics together, but the demonstration result has not been published yet.
There is a need for a new prebiotic composition to enhance the proliferative effect of BB12.
Disclosure of Invention
The present invention provides a prebiotic composition that significantly promotes the proliferation of BB12. On the basis, the invention also provides a composition (synbiotic composition) containing the prebiotic composition and BB12, and food application and medical application of the prebiotic composition and the composition.
The invention relates to a prebiotic composition, which comprises the following components:
0.5 to 18 parts by weight of oligosaccharide (e.g., 0.6 part by weight, 0.7 part by weight, 0.8 part by weight, 0.9 part by weight, 1 part by weight, 1.5 part by weight, 2 parts by weight, 2.5 parts by weight, 3 parts by weight, 3.5 parts by weight, 4 parts by weight, 4.5 parts by weight, 5 parts by weight, 5.5 parts by weight, 6 parts by weight, 6.5 parts by weight, 7 parts by weight, 7.5 parts by weight, 8 parts by weight, 8.5 parts by weight, 9 parts by weight, 9.5 parts by weight, 10 parts by weight, 10.5 parts by weight, 11 parts by weight, 11.5 parts by weight, 12 parts by weight, 12.5 parts by weight, 13 parts by weight, 13.5 parts by weight, 14 parts by weight, 14.5 parts by weight, 15 parts by weight, 15.5 parts by weight, 17 parts by weight)
1 part by weight of isomerized lactose;
wherein the oligosaccharide is at least one selected from galacto-oligosaccharide, fructo-oligosaccharide and raffinose.
In some embodiments of the first aspect of the present invention, the oligosaccharide is a galactooligosaccharide and/or a fructooligosaccharide.
In certain embodiments of the first aspect of the present invention, the oligosaccharide is 1 to 4 parts by weight.
In some embodiments of the first aspect of the present invention, the prebiotic composition further comprises an additional prebiotic ingredient.
In some embodiments of the invention, the prebiotic composition further comprises at least one prebiotic component selected from the group consisting of human milk oligosaccharides, fructooligosaccharides, transgalactosyl oligosaccharides, soy oligosaccharides, isomalto-oligosaccharides, neosugars, lactitol oligosaccharides, mannooligosaccharides, gentiooligosaccharides, xylooligosaccharides, polydextrose, dextran, polyfructose, chicory, resistant dextrins, resistant starch, gum arabic, locust bean gum, and guar gum.
In some embodiments of the first aspect of the present invention, the oligosaccharide is a galactooligosaccharide; preferably, the galactooligosaccharide is 2 to 16 parts by weight, such as 2.5 parts by weight, 3 parts by weight, 3.5 parts by weight, 4 parts by weight, 4.5 parts by weight, 5 parts by weight, 5.5 parts by weight, 6 parts by weight, 6.5 parts by weight, 7 parts by weight, 7.5 parts by weight, 8 parts by weight, 8.5 parts by weight, 9 parts by weight, 9.5 parts by weight, 10 parts by weight, 10.5 parts by weight, 11 parts by weight, 12 parts by weight, 13 parts by weight, 14 parts by weight, 15 parts by weight.
In some embodiments of the first aspect of the present invention, the oligosaccharide is a fructooligosaccharide; preferably, the fructooligosaccharide is 1 to 3.7 parts by weight, such as 1.5 parts by weight, 2 parts by weight, 2.5 parts by weight, 3 parts by weight, 3.5 parts by weight.
A second aspect of the invention relates to a composition comprising a prebiotic composition according to the first aspect of the invention and a probiotic, which is bifidobacterium animalis (bifidobacterium animalis).
In some embodiments of the second aspect of the invention, the probiotic is bifidobacterium animalis BB12.
In some embodiments of the second aspect of the present invention, the composition is a synbiotic composition.
In some embodiments of the second aspect of the present invention, the composition is a synbiotic formulation.
In some embodiments of the invention, the types of synbiotic formulations include, but are not limited to, solutions, powders, tablets, granules, pills, emulsions, suspensions, drops, sprays, ointments, gels, pastes, and the like.
In some embodiments of the second aspect of the invention, the probiotic is not less than 10 per 1-30 g of prebiotic composition 8 CFU。
In some embodiments of the second aspect of the invention, the ratio of prebiotic composition to probiotic is 1 (10) 8 ~10 13 ) g/CFU, e.g. 1 9 g/CFU、1:10 10 g/CFU、1:10 11 g/CFU、1:10 12 g/CFU。
In a third aspect, the present invention relates to a method for culturing or promoting the proliferation of bifidobacterium animalis, comprising the steps of:
the composition according to the second aspect of the present invention is added to a culture medium and cultured for 6 to 30 hours (e.g., 7 hours, 8 hours, 9 hours, 10 hours, 12 hours, 14 hours, 16 hours, 18 hours, 20 hours, 21 hours, 23 hours, 25 hours, 27 hours, 29 hours) at 30 to 40 ℃ (e.g., 31 ℃, 32 ℃, 33 ℃, 34 ℃, 35 ℃, 36 ℃, 37 ℃, 38 ℃, 39 ℃) to obtain a culture.
In some embodiments of the third aspect of the invention, the medium is MRS +0.05% cysteine medium.
In some embodiments of the invention, MRS +0.05% cysteine medium refers to de Man Rogosa Sharpe (MRS) broth (Difco, detroit, md.) medium containing 0.05% (W/W) cysteine.
In some embodiments of the third aspect of the invention, the weight of the prebiotic composition in the composition is between 0.4% and 4% of the weight of the medium, e.g. 0.8%, 1%, 2%, 3%.
In some embodiments of the third aspect of the invention, the bifidobacterium animalis is bifidobacterium animalis BB12.
In a fourth aspect, the invention relates to a culture comprising bifidobacterium animalis produced by the method of the third aspect of the invention.
In some embodiments of the fourth aspect of the invention, the bifidobacterium animalis is bifidobacterium animalis BB12.
In some embodiments of the fourth aspect of the invention, the Bifidobacterium animalis in the culture has an OD600 reading of ≥ 0.38, preferably 0.4-0.5, e.g. 0.39, 0.42, 0.44, 0.45, 0.46, 0.48, 0.50, 0.52, 0.55, 0.57, 0.60, 0.70, 0.80, 0.90.
A fifth aspect of the invention relates to a food or pharmaceutical product comprising a prebiotic composition according to the first aspect of the invention and bifidobacterium animalis, or a composition according to the second aspect of the invention, or a culture comprising bifidobacterium animalis according to the fourth aspect of the invention.
In some embodiments of the fifth aspect of the invention, the food or pharmaceutical product has a bifidobacterium animalis content of not less than 10 per 1-30 g prebiotic composition 8 CFU。
In some embodiments of the fifth aspect of the invention, the ratio of prebiotic composition to Bifidobacterium animalis in the food or pharmaceutical product is 1 (10) 8 ~10 13 ) g/CFU, e.g. 1 9 g/CFU、1:10 10 g/CFU、1:10 11 g/CFU、1:10 12 g/CFU。
In some embodiments of the fifth aspect of the invention, the bifidobacterium animalis is bifidobacterium animalis BB12.
In some embodiments of the fifth aspect of the present invention, the food product is selected from at least one of dairy products, cereal products, soy products, condiments, ice products and beverages, such as dairy products.
In some embodiments of the fifth aspect of the present invention, the dairy product is selected from at least one of a group consisting of a sterilized milk, a reconstituted milk, a yogurt milk, a milk powder, a milk formula, a condensed milk, a cheese, a casein, a whey powder and a milk fat, preferably a milk formula, more preferably a milk formula for infants.
A sixth aspect of the invention relates to the use of a prebiotic composition and bifidobacterium animalis in the preparation of a synbiotic formulation according to the first aspect of the invention.
In some embodiments of the sixth aspect of the invention, the bifidobacterium animalis is bifidobacterium animalis BB12.
In some embodiments of the sixth aspect of the invention, the bifidobacterium animalis is not less than 10 per 1-30 g of prebiotic composition 8 CFU。
In some embodiments of the sixth aspect of the invention, the ratio of prebiotic composition to Bifidobacterium animalis is 1 (10) 8 ~10 13 ) g/CFU, e.g. 1 9 g/CFU、1:10 10 g/CFU、1:10 11 g/CFU、1:10 12 g/CFU。
The seventh aspect of the invention relates to the prebiotic composition and bifidobacterium animalis of the first aspect of the invention, or the use of the composition of the second aspect of the invention in culturing or promoting the proliferation of bifidobacterium animalis.
In some embodiments of the seventh aspect of the invention, the bifidobacterium animalis is bifidobacterium animalis BB12.
In some embodiments of the seventh aspect of the invention, the bifidobacterium animalis is not less than 10 per 1-30 g of prebiotic composition 8 CFU。
In some embodiments of the seventh aspect of the invention, the ratio of prebiotic composition to Bifidobacterium animalis is 1 (10) 8 ~10 13 ) g/CFU, e.g. 1 9 g/CFU、1:10 10 g/CFU、1:10 11 g/CFU、1:10 12 g/CFU。
An eighth aspect of the present invention relates to the use of the prebiotic composition according to the first aspect of the present invention and bifidobacterium animalis, or the composition according to the second aspect of the present invention, or the culture containing bifidobacterium animalis according to the fourth aspect of the present invention in food, or in the manufacture of a medicament for the prevention or treatment of diarrhea, intestinal flora disturbance caused by antibiotics, intestinal flora disturbance caused by iron supplementation, or respiratory infection.
In some embodiments of the eighth aspect of the invention, the bifidobacterium animalis is bifidobacterium animalis BB12.
In some embodiments of the eighth aspect of the invention, the bifidobacterium animalis is not less than 10 per 1-30 g of prebiotic composition 8 CFU。
In some embodiments of the eighth aspect of the invention, the ratio of prebiotic composition to Bifidobacterium animalis is 1 (10) 8 ~10 13 ) g/CFU, e.g. 1 9 g/CFU、1:10 10 g/CFU、1:10 11 g/CFU、1:10 12 g/CFU。
In some embodiments of the invention, the galactooligosaccharides have a relative molecular mass of 300 to 2000.
In some embodiments of the present invention, the galactooligosaccharide may be a single structure galactooligosaccharide or a mixture of galactooligosaccharides with different structures.
In some embodiments of the invention, the galactooligosaccharide is selected from at least one of galactooligosaccharide, galactooligosaccharide pentasaccharide and galactooligosaccharide hexasaccharide.
In some embodiments of the invention, the galactooligosaccharide may be provided in the form of a galactooligosaccharide powder or a galactooligosaccharide solution.
In some embodiments of the invention, the galactooligosaccharide content of the dry weight of the lacto-oligosaccharide powder or galactooligosaccharide solution is greater than or equal to 57%.
In some embodiments of the invention, the galactooligosaccharide complies with the regulation of ministry of health of the people's republic of china No. 20, 2008.
In some embodiments of the present invention, the fructooligosaccharide may be inulin fructooligosaccharide or sucrose fructooligosaccharide, or a mixture thereof.
In some embodiments of the invention, the fructooligosaccharide may be of the GFn type or the Fn type alone or in combination. Wherein, the GFn type can be a single structure with n taking a fixed value, and can also be a mixture of different GFn types; the Fn type may be a single structure or a mixture of different Fn types.
In some embodiments of the invention, the fructooligosaccharides comply with the regulations of GB/T23528-2009 fructooligosaccharides.
In some embodiments of the invention, the isomerized lactose complies with the specifications in GB 1886.176-2016 for isomerized lactose.
In some embodiments of the present invention, the raffinose meets the specifications of "national food safety standard food nutrient supplement raffinose" of GB 31618-2014.
The invention has the following beneficial effects:
1. the prebiotic composition can obviously promote the proliferation of BB12.
2. The composition (synbiotic composition) of the present invention is useful for preventing or treating diarrhea, intestinal flora disturbance caused by antibiotics, intestinal flora disturbance caused by iron supplementation, or respiratory infectious diseases.
Drawings
In order that the present disclosure may be more readily and clearly understood, reference is now made to the following detailed description of the present disclosure taken in conjunction with the accompanying drawings, in which:
FIG. 1 is a graphical representation of the results of a prior study of the health and disease relationship of bifidobacteria to humans;
FIG. 2 is the results of OD600 readings for various combinations in example 1 of the present invention;
FIG. 3 shows the results of various combinations of OD600 readings in example 2 of the present invention.
Detailed Description
The embodiments of the present invention will now be described more fully hereinafter with reference to the accompanying examples, in which some, but not all embodiments of the invention are shown. The following description of at least one exemplary embodiment is merely illustrative in nature and is in no way intended to limit the invention, its application, or uses. All other embodiments, which can be derived by a person skilled in the art from the embodiments given herein without making any creative effort, shall fall within the protection scope of the present invention.
Example 1
Bifidobacterium animalis BB12 strain was supplied by Kehansen.
(1) BB12 strain was placed in de Man Rogosa Sharpe (MRS) broth (Difco, detroit, md.) supplemented with 0.5g/L of L-cysteine and incubated at 37 ℃ for 24h in an anaerobic environment to obtain a culture. The cultures were then passaged twice on semisynthetic MRS medium (sMRS) +0.5 g/L-cysteine supplemented with 1% (w/v) sterile-filtered glucose as the sole carbohydrate source; after the second passage, the resulting culture was used as an inoculum for future use. Wherein, the mother liquor of each carbon source is filtered and sterilized by a filter with the pore diameter of 0.22 micron and is used at the final concentration of 1 percent.
(2) Let Galactooligosaccharide (GOS) group, isomerized Lactose (LOS) group, GOS/LOS (weight ratio 1). Each group was inoculated with BB12 in MRS +0.05% cysteine medium at an OD600 reading of 0.1 and added with 1% Galactooligosaccharide (GOS), 1% isomerized Lactose (LOS), 1% GOS/LOS (1 by weight) 10 1CFU/g, the temperature of the culture is 35-38 ℃, OD600 in each group of culture medium is measured by High Performance Liquid Chromatography (HPLC) after 15 hours of culture,the results are shown in FIG. 2.
As can be seen from fig. 2, the proliferation amount of BB12 in the GOS/LOS (weight ratio 4. But the pH of each broth was not significantly different. This suggests that a certain proportion of GOS and LOS synergistically promote the proliferation of BB12.
Example 2
(1) Same as in step (1) of example 1.
(2) The Fructooligosaccharide (FOS) group, the isomerized Lactose (LOS) group, the FOS/LOS (1 by weight), the FOS/LOS (4 by weight. Each group was inoculated with BB12 in MRS +0.05% cysteine medium according to OD600 reading 0.1 and added with 1% Fructooligosaccharide (FOS), 1% isomerized Lactose (LOS), 1% FOS/LOS (1 in weight 10 1CFU/g, at a temperature of 35 to 38 ℃ for 15 hours, and then measured for OD600 by High Performance Liquid Chromatography (HPLC), the results are shown in FIG. 3.
As can be seen from fig. 3, the proliferation amount of BB12 in FOS/LOS (weight ratio 1. But the pH of each broth was not significantly different. This indicates that a certain proportion of FOS and LOS synergistically promote the proliferation of BB12.
It should be understood that the above examples are only for clarity of illustration and are not intended to limit the embodiments. Other variations and modifications will be apparent to persons skilled in the art in light of the above description. And are neither required nor exhaustive of all embodiments. And obvious variations or modifications derived therefrom are intended to be within the scope of the invention.
[1]Arboleya S,Watkins C,Stanton C,Ross RP.Gut Bifidobacteria Populations in Human Health and Aging.Front Microbiol.2016Aug 19;7:1204.
[2]Weizman Z,Alsheikh A.Safety and tolerance of a probiotic formula in early infancy comparing two probiotic agents:a pilot study[J].Journal of the American College of Nutrition,2006,25(5):415-419.
[3]Tan T P,Ba Z,Sanders M E,et al.Safety of Bifidobacterium animalis Subsp.Lactis(B.lactis)Strain BB-12-Supplemented Yogurt in Healthy Children[J].J Pediatr Gastroenterol Nutr,2017,64(2):302-309.
[4]Merenstein D J,Tan T P,Molokin A,et al.Safety of Bifidobacterium animalis subsp.lactis(B.lactis)strain BB-12-supplemented yogurt in healthy adults on antibiotics:a phase I safety study.[J].Gut Microbes,2015,6(1):66-77.
[5]Saavedra J M,Bauman N A,Perman J A,et al.Feeding of Bifidobacterium bifidum and Streptococcus thermophilus to infants in hospital for prevention of diarrhoea and shedding of rotavirus[J].Lancet,1994,344(8929):1046-1049.
[6]Chouraqui J P,Mc V E L.Acidified milk formula supplemented with bifidobacterium lactis:impact on infant diarrhea in residential care settings[J].J Pediatr Gastroenterol Nutr,2004,38(3):288-292.
[7]Zvi W,Ghaleb A,Ahmed A.Effect of a probiotic infant formula on infections in child care centers:comparison of two probiotic agents[J].Pediatrics,2005,115(1):5-9.
[8]Samuli R,Seppo S,Erika I.Specific probiotics in reducing the risk of acute infections in infancy--a randomised,double-blind,placebo-controlled study[J].British Journal of Nutrition,2009,101(11):1722-1726.
[9]Taipale T J,
Figure BDA0002251528160000121
K,Isolauri E,et al.Bifidobacterium animalis subsp.lactis BB-12 in reducing the risk of infections in early childhood[J].Pediatric research,2015,79(1-1):65.
[10]Ruchika M,Corinna K,Janko S,et al.Effects of Bifidobacterium lactis Bb12supplementation on body weight,fecal pH,acetate,lactate,calprotectin,and IgA in preterm infants[J].Pediatric Research,2008,64(4):418-422.
[11]Samuli R,Heikki A,Erika I.Specific probiotics in enhancing maturation of IgA responses in formula-fed infants[J].Pediatric Research,2006,60(2):221-224.
[12]Xinias I,Analitis A,Mavroudi A,et al.Innovative Dietary Intervention Answers to Baby Colic[J].Pediatric Gastroenterology Hepatology&Nutrition,2017,20(2):100-106.

Claims (9)

1. A composition comprises prebiotic composition and Bifidobacterium animalis BB12, wherein the ratio of prebiotic composition to Bifidobacterium animalis BB12 is 1 (10) 8 ~10 11 ) g/CFU; wherein,
the prebiotic composition consists of the following components:
galacto-oligosaccharide 4 parts by weight
1 part by weight of isomerized lactose;
alternatively, the prebiotic composition is comprised of:
1 part by weight of fructo-oligosaccharide
Isomerized lactose 1 part by weight.
2. A method for culturing Bifidobacterium animalis BB12 or promoting the proliferation of Bifidobacterium animalis BB12, comprising the steps of:
the composition of claim 1 is added to MRS +0.05% cysteine medium, the weight of the prebiotic composition is 0.4-2% of the weight of the medium, and the culture is obtained by culturing at 30-40 ℃ for 14-16 hours.
3. A culture comprising bifidobacterium animalis BB12 produced by the method of claim 2.
4. A food or pharmaceutical product comprising the composition of claim 1 or comprising the culture of bifidobacterium animalis BB12 of claim 3.
5. The food product of claim 4, wherein the food product is selected from at least one of dairy products, cereal products, soy products, condiments, ice products, and beverages.
6. A food product according to claim 4 wherein the food product is a dairy product.
7. The food product of claim 5, wherein the dairy product is selected from at least one of the group consisting of sterilized milk, reconstituted milk, yogurt milk, powdered milk formula, condensed milk, cheese, casein, whey powder, and milk fat.
8. Use of the composition of claim 1 for culturing bifidobacterium animalis BB12 or promoting the proliferation of bifidobacterium animalis BB12.
9. Use of the composition of claim 1 or the culture containing bifidobacterium animalis BB12 of claim 3 in the preparation of a food or a medicament for the prevention or treatment of diarrhea, intestinal flora disturbance caused by antibiotics, intestinal flora disturbance caused by iron supplementation or respiratory infectious diseases.
CN201911036025.6A 2019-10-29 2019-10-29 Prebiotic compositions, and uses thereof Active CN112741334B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201911036025.6A CN112741334B (en) 2019-10-29 2019-10-29 Prebiotic compositions, and uses thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201911036025.6A CN112741334B (en) 2019-10-29 2019-10-29 Prebiotic compositions, and uses thereof

Publications (2)

Publication Number Publication Date
CN112741334A CN112741334A (en) 2021-05-04
CN112741334B true CN112741334B (en) 2023-03-21

Family

ID=75640100

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201911036025.6A Active CN112741334B (en) 2019-10-29 2019-10-29 Prebiotic compositions, and uses thereof

Country Status (1)

Country Link
CN (1) CN112741334B (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115474695B (en) * 2021-05-31 2024-01-19 仙乐健康科技股份有限公司 A preparation for regulating intestinal microbial balance of host
CN116196319B (en) * 2021-11-30 2024-06-04 内蒙古伊利实业集团股份有限公司 Use of oligosaccharides for protecting cartilage

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101310606A (en) * 2007-05-24 2008-11-26 大连森佰澳科技有限公司 Liquid milk products containing bifidobacteria function signal and prebiotics
CN101496822A (en) * 2009-02-18 2009-08-05 上海谱莱生物技术有限公司 Composite probiotics micro-ecological formulation and preparation method
CN102524391B (en) * 2010-12-21 2013-11-13 内蒙古蒙牛乳业(集团)股份有限公司 Fermented dairy product containing compound prebiotic and probiotic group
CN104413334A (en) * 2013-08-30 2015-03-18 深圳华大基因科技有限公司 Edible composition as well as preparation method and application thereof
CN107981359A (en) * 2017-12-12 2018-05-04 河北三元食品有限公司 Prebiotic compositions and its application
CN108208843A (en) * 2017-12-30 2018-06-29 广州润虹医药科技股份有限公司 A kind of health composition for adjusting intestinal flora and application thereof
CN109645501A (en) * 2019-01-14 2019-04-19 云浮市新金山生物科技股份有限公司 A kind of galactooligosaccharide composition and its application of defaecation and reduction flatulence

Also Published As

Publication number Publication date
CN112741334A (en) 2021-05-04

Similar Documents

Publication Publication Date Title
US10716321B2 (en) Oligosaccharide mixture and food product comprising same
US10124016B2 (en) Immune system stimulating nutrition
US8591919B2 (en) Synergistic mixture of beta-galacto-oligosaccharides with beta-1,3 and beta -1,4/1,6 linkages
EP1355542B2 (en) Nutritional composition with health promoting action containing oligosaccharides
RU2731154C2 (en) Composition for use in improving stool consistence or frequency in infants or young children
TW201304692A (en) Synbiotic combination of probiotic and human milk oligosaccharides to promote growth of beneficial microbiota
TW201225852A (en) Oligosaccharide mixture and food product comprising this mixture, especially infant formula
US20100330040A1 (en) Composition with synbiotics
PT1871400E (en) Uronic acid and probiotics
TW201302205A (en) Composition for use in the preventing of acute respiratory tract infections and/or relieving symptoms of said infections
TW201233334A (en) Human milk oligosaccharides to promote growth of beneficial bacteria
EP2117355A1 (en) Method of improving skills with a composition comprising non-digestible saccharide
AU2022203298A1 (en) Nutritional compositions and infant formulas comprising a mix of oligosaccharides and optionally bifidobacterium lactis for preventing, treating or reducing the severity of non-rota virus-associated diarrhoea
CN112741334B (en) Prebiotic compositions, and uses thereof
Moro et al. Reproducing the bifidogenic effect of human milk in formula‐fed infants: why and how?
US20160206658A1 (en) Nutrition for prevention of infections
WO2021093880A1 (en) Synergistic combination of butyric-acid-producing prebiotics and probiotics
CN114568699B (en) Composition containing galactooligosaccharides and probiotics and application thereof
CN114568701B (en) Composition containing fructo-oligosaccharide and probiotics and application thereof
Solkar et al. Pre and Probiotics In Paediatrics
EP4304378A1 (en) Aqueous composition comprising gos and hmo
Kim et al. The effect of inulin/fructo-oligosaccharide as a prebiotic ingredient in baby formulae
CN103533851A (en) Prebiotic carbohydrate compositions
TW201249349A (en) Milk oligosaccharide-galactooligosaccharide composition for infant formula containing the soluble oligosaccharide fraction present in milk, and having a low level of monosaccharides, and a process to produce the composition
Vandenplas et al. Prebiotics and Infant Nutrition

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant